

• **Suicidal ideation:** Assess for suicidal thoughts and behavior; more common in young adults

**Evaluate:**

• Therapeutic response: decrease in postpartum depression, improved mood

**Teach patient/family:**

- Reason for product and expected result
- To discuss all Rx, OTC, herbals and supplements with healthcare provider
- To report pain, inflammation at injection site

• **Excessive sedation and sudden loss of consciousness:** excessive sedation or loss of consciousness can occur; checking q2hr for these symptoms will be required; if these occur, tell your healthcare provider

• A family member or caregiver needs to help care for you and your children during the infusion

• Not to drive or engage in hazardous tasks while sleepiness occurs

• Not to use alcohol or other CNS depressants

• **Pregnancy/breastfeeding:** to identify if pregnancy is planned or suspected or if breastfeeding; if pregnant, register with the National Pregnancy Registry for Antidepressants at 1-844-405-6185 or visit <https://womensmentalhealth.org/clinical-and-research-programs/pregnancy-registry/antidepressants/>

### caplacizumab (Rx)

(kap' luh-sih'-zoo-mab)

Cablivi

*Func. class.:* Hematologic agent

**USES:** Acquired thrombotic thrombocytopenia purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy

### CONTRAINDICATIONS

Hypersensitivity

### DOSAGE AND ROUTES

• **Adult: IV** 11 mg once at least 15 min before plasma exchange on the first day

of treatment (initial dose); subcut 11 mg daily starting after the completion of plasma exchange on day 1 and continuing for 30 days after the last daily plasma exchange; treatment may be extended for a maximum of 28 days after the initial treatment (maintenance dose)

### cladribine (Rx)

(klad'-dri-been)

Leustatin, Mavenclad

*Func. class.:* Multiple sclerosis agent/antineoplastic

*Chem. class.:* Purine nucleoside antimetabolite

**ACTION:** May be lymphocyte depletion through cytotoxic effects on B and T lymphocytes through impairment of DNA synthesis

**USES:** Relapsing multiple sclerosis, active hairy-cell leukemia

**CONTRAINDICATIONS:** Breast-feeding, HIV, TB

**Black Box Warning:** Pregnancy

**Precautions:**

Contraceptive requirements, hepatic disease, infection, renal disease, progressive multifocal, leukoencephalopathy, neonates, premature

**Black Box Warning:** Bone marrow suppression, neurotoxicity, nephrotoxicity, new primary malignancy, reproductive risk; requires an experienced clinician

### DOSAGE AND ROUTES

**Relapsing forms of multiple sclerosis**

**Adults: PO** 1.75 mg/kg per treatment course divided into 2 cycles and given as divided doses of 1 or 2 tablets daily over 4 or 5 days for each cycle with second cycle starting 23 to 27 days after the last dose of first cycle; give a second course at least 43 wk after the last dose of the